Quality of life and comorbidity in localized malignant melanoma: results of a German population-based cohort study

Authors

  • Gabriele Schubert-Fritschle PhD,

    1. Munich Cancer Registry, Munich Cancer Centre, Department of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians University (LMU), Munich, Germany
    Search for more papers by this author
  • Anne Schlesinger-Raab MD, MPH,

    1. Munich Cancer Registry, Munich Cancer Centre, Department of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians University (LMU), Munich, Germany
    Search for more papers by this author
  • Rüdiger Hein MD,

    1. Clinic and Policlinic for Dermatology and Allergology, Technical University Munich, Munich, Germany
    Search for more papers by this author
  • Wilhelm Stolz MD,

    1. Clinic for Dermatology, Allergology and Environmental Medicine, Hospital Munich-Schwabing, Munich, Germany
    Search for more papers by this author
  • Matthias Volkenandt MD,

    1. Clinic and Policlinic for Dermatology and Allergology, LMU, Munich, Germany
    Search for more papers by this author
  • Dieter Hölzel PhD,

    1. Munich Cancer Registry, Munich Cancer Centre, Department of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians University (LMU), Munich, Germany
    Search for more papers by this author
  • Jutta Engel MD, MPH

    1. Munich Cancer Registry, Munich Cancer Centre, Department of Medical Informatics, Biometry and Epidemiology (IBE), Ludwig-Maximilians University (LMU), Munich, Germany
    Search for more papers by this author

  • Funding: This study was funded in part by the Wilhelm Sander Foundation and the Bavarian Ministry of Health.

  • Conflicts of interest: None.

Anne Schlesinger-Raab, md, mph
Tumorregister München
Klinikum Grosshadern
Marchioninistrasse 15
D-81377 Munich
Germany
E-mail: schlesi@ibe.med.uni-muenchen.de

Abstract

Background  Incidences of malignant melanoma continue to increase in fair-skinned populations. At least 80% of patients are diagnosed with localized disease and can expect a 5-year relative survival rate of >90%. Given that the median age at diagnosis of malignant melanoma is 59 years, many patients already suffer chronic diseases when they are confronted with cancer.

Objectives  The aim of this study was to analyze the effect of additional chronic diseases on health-related quality of life (QoL) in a population-based cohort of melanoma patients two years after presumably curative treatment.

Methods  In 2003–2004, 1085 patients with localized malignant melanoma were recruited from the population-based Munich Cancer Registry to answer validated QoL questionnaires. Information about comorbidities was also obtained. Factors predicting QoL were analyzed using multivariate logistic regression models.

Results  A total of 781 patients (72%) returned completed questionnaires, of which 664 (61%) could be included in the analyses. Quality of life scores and differences in subgroups (e.g. sex and age) were essentially similar to those in the general population. Age, number of comorbidities, and several chronic diseases (e.g. heart and kidney disease, diabetes, former depression) were the strongest predicting factors and influenced almost every aspect of QoL.

Conclusions  Localized malignant melanoma does not worsen QoL per se, compared with QoL in the general population. Comorbidities have similar effects on QoL in malignant melanoma patients as they do in the general population. Therefore, cohorts of patients with localized malignant melanoma can represent a basis for comparisons with other cohorts of cancer patients to determine the respective impacts of cancer-related and non-cancer-related factors on QoL.

Ancillary